Wedbush Reaffirms “Neutral” Rating for Intellia Therapeutics (NASDAQ:NTLA)
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “neutral” rating restated by Wedbush in a report issued on Thursday,RTT News reports. They currently have a $7.00 target price on the stock, down from their prior target price of $10.00. Wedbush’s price objective would suggest a potential upside of 0.14% from the stock’s current […]
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “neutral” rating restated by Wedbush in a report issued on Thursday,RTT News reports. They currently have a $7.00 target price on the stock, down from their prior target price of $10.00. Wedbush’s price objective would suggest a potential upside of 0.14% from the stock’s current […]
